Page last updated: 2024-12-05

1-naphthylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 1-Naphthylamine: A Controversial Compound in Research

1-Naphthylamine (1-NA) is a colorless to pale yellow solid, often used in research due to its unique chemical properties. However, its use is **highly restricted** due to its serious **carcinogenic nature**.

Here's a breakdown of 1-NA's importance and limitations:

**Importance:**

* **Dye and Polymer Synthesis:** 1-NA is a key precursor in the production of various azo dyes used in textiles, paper, and leather. It also finds application in the synthesis of certain polymers.
* **Analytical Chemistry:** 1-NA is used in analytical procedures like spectrophotometry and chromatography due to its distinct optical properties.
* **Research Studies:** Despite its hazards, 1-NA remains vital for specific research purposes, including:
* **Cancer Research:** Studying its carcinogenic mechanism can contribute to understanding cancer development and potential therapeutic targets.
* **Environmental Monitoring:** 1-NA can be used as a model compound to investigate the environmental fate of aromatic amines, helping develop strategies for pollution control.
* **Drug Development:** Some research focuses on using 1-NA derivatives as potential cancer therapeutics.

**Limitations and Risks:**

* **Carcinogenesis:** 1-NA is **highly carcinogenic**, specifically linked to bladder cancer. This risk is significant even at low exposure levels.
* **Strict Regulations:** Due to its toxicity, 1-NA's use and handling are heavily regulated. Its production and use are subject to strict control and monitoring in most countries.
* **Alternatives:** Researchers actively seek safer alternatives for 1-NA's applications, aiming to minimize the risk of exposure.

**Conclusion:**

1-Naphthylamine is a valuable compound for specific research applications, but its extreme carcinogenic nature necessitates careful handling and strict safety precautions. Research continues to explore safer alternatives and minimize its use while harnessing its unique chemical properties responsibly.

1-Naphthylamine: A suspected industrial carcinogen (and listed as such by OSHA). Its N-hydroxy metabolite is strongly carcinogenic and mutagenic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

naphthylamine : A primary arylamine that is naphthalene substituted by an amino group at unspecified position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

1-naphthylamine : A naphthylamine that is naphthalene substituted by an amino group at position 1. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8640
CHEMBL ID57394
CHEBI ID50450
SCHEMBL ID9029
SCHEMBL ID8059977
SCHEMBL ID7738276
MeSH IDM0023169

Synonyms (113)

Synonym
CHEBI:50450 ,
1-naphthalamine
1-naftilamina
alpha-aminonaphthalene
1-naphthylamin
alpha-naphthylamine
naphthalen-1-ylamine
1-aminonaphthalene
134-32-7
1-naphthylamine
inchi=1/c10h9n/c11-10-7-3-5-8-4-1-2-6-9(8)10/h1-7h,11h
1-naphthalenamine
naphthalen-1-amine
NCGC00091092-01
c.i. azoic diazo component 114
fast garnet base b
ci 37265
ccris 423
rcra waste number u167
alpha-naftalamin [czech]
naphthalidam
ci azoic diazo component 114
alpha-naftylamin [czech]
naphthalidine
fast garnet b base
rcra waste no. u167
1-aminonaftalen [czech]
alfa-naftyloamina [polish]
1-naphthylamine, technical grade
einecs 205-138-7
ai3-00085
hsdb 1080
1-naftylamine [dutch]
alfanaftilamina [italian]
un2077
1-naftylamin [czech]
1-naphthylamin [german]
1-naftilamina [spanish]
brn 0386133
STK301604
1-naphthylamine, analytical standard
1-naphthylamine, >=99.0%
AC-10635
CHEMBL57394 ,
N0052
bdbm50282489
AKOS000119159
A806762
NCGC00091092-03
NCGC00091092-02
cas-134-32-7
dtxsid7020920 ,
NCGC00256472-01
dtxcid30920
tox21_302805
tox21_201233
NCGC00258785-01
naphthalen-1-yl-amine
N0165
BBL013044
naphthylamine
naphthaleneamine
25168-10-9
1-naphylamine
alfa-naftyloamina
alpha-naftylamin
9753i242r5 ,
1-naftylamine
ec 205-138-7
alpha-naftalamin
4-12-00-03009 (beilstein handbook reference)
alpha-naphthylamine [un2077] [poison]
1-aminonaftalen
alfanaftilamina
unii-9753i242r5
1-naftylamin
FT-0608132
FT-0622384
c.i. 37265
.alpha.-aminonaphthalene
.alpha.-naphthylamine
1-naphtylamine
1-naphthylamine [hsdb]
1-naphthylamine [mi]
1-naphthylamine [iarc]
AB00443633-03
SCHEMBL9029
SCHEMBL8059977
naphthyl-amine
1-aminonaphthalen
1-naphthaleneamine
1-amino napthalene
1-napthylamine
aminonaphthalene
1-naphthalenylamine
1-naphthyl amine
SCHEMBL7738276
.alpha.-naftylamin
un 2077
.alpha.-naftalamin
W-108286
mfcd00004016
F2190-0453
naphthalenamine
nitrate reagent a, for microbiology
1-naphthylamine, p.a., 99.0%
Z57127984
NCGC00091092-04
1-naphthaylamine
AS-13623
Q161655
5I2 ,
EN300-18066

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The side-effect profile of sertraline was similar in young and old, and individual side effects did not make a notable contribution to the discontinuation rate."( Toleration and safety of sertraline: experience worldwide.
Doogan, DP, 1991
)
0.28
" In an attempt to circumvent these adverse effects, many antidepressants were prescribed at less than therapeutic doses, resulting in a high probability of inadequate treatment, relapse, or recurrence."( Striking a balance between safety and efficacy: experience with the SSRI sertraline.
Casey, DE, 1994
)
0.29
" The incidence of adverse events was similar for both treatments; 40."( Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression.
Aguglia, E; Bolino, F; Casacchia, M; Cassano, GB; Faravelli, C; Ferrari, G; Giordano, P; Pancheri, P; Ravizza, L; Trabucchi, M, 1993
)
0.29
" The fates of SSRI-associated sexual adverse effects and clinical managements of restoring these side effects were described."( Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients.
Hsu, JH; Shen, WW, 1995
)
0.29
"With some limitations in interpreting the data, the findings of this study suggest that SSRI-associated female sexual dysfunction occurs at a higher rate than we previously thought, equal potentials in implicating female sexual side effects among three SSRIs, and the absence or the low incidence of female sexual adverse effects from bupropion, and that these side effects can be managed by waiting for a spontaneous remission, dosage reduction of SSRIs, substitution with bupropion and other antidepressants, or the use of an antidote."( Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients.
Hsu, JH; Shen, WW, 1995
)
0.29
"To study the adverse drug reaction (ADR) profile of selective serotonin re-uptake inhibitors (SSRI) in Belgium and the Netherlands."( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands].
Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996
)
0.29
"All adverse reactions of fluoxetine, fluvoxamine, paroxetine and sertraline, reported between the moment of registration of these drugs and January 1st 1995, were assessed for causality."( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands].
Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996
)
0.29
"At the national monitoring centres of Belgium and of the Netherlands adverse reactions were reported 78 and 537 times, respectively."( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands].
Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996
)
0.29
" More adverse reactions were reported in the Netherlands than in Belgium."( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands].
Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996
)
0.29
" We have addressed the question of whether there is a 'serotonin withdrawal syndrome' by analysis of spontaneous reports of suspected adverse drug reactions (ADRs) associated with four SSRIs."( A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.
MacKay, AV; Price, JS; Waller, PC; Wood, SM, 1996
)
0.29
" Overall, 27% of the SSRI-treated patients had no adverse sexual side effects; in contrast, 86% of patients treated with bupropion had no adverse sexual effects, and 77% of bupropion-treated patients reported at least one aspect of heightened sexual functioning."( Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline.
DePalma, RL; Katholi, CR; Modell, JD; Modell, JG, 1997
)
0.3
"SSRI-induced adverse sexual effects appear to be the rule rather than the exception and may be substantially underreported unless patients are specifically asked about the effects of these medications on various aspects of sexual function."( Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline.
DePalma, RL; Katholi, CR; Modell, JD; Modell, JG, 1997
)
0.3
"Blood level monitoring helps to determine the therapeutic and toxic ranges for anticonvulsants and antidepressants."( Lamotrigine toxicity secondary to sertraline.
Gerner, R; Kaufman, KR, 1998
)
0.3
" Of the three toxicants, the most marked perturbations were induced by ANIT exposure, then NI, thereby indicating the effects of ANIT, NI and NA toxicity were distinct, with ANIT being the most, and NA the least, toxic of the three compounds."( Chemometric analysis of biofluids following toxicant induced hepatotoxicity: a metabonomic approach to distinguish the effects of 1-naphthylisothiocyanate from its products.
Azmi, J; Griffin, JL; Holmes, E; Nicholson, JK; Shore, RF, 2005
)
0.33
" Both drug regimens were well tolerated, without any serious adverse events."( Randomized, Double-Blind, Placebo-Controlled Studies to Assess Safety and Prophylactic Efficacy of Naphthoquine-Azithromycin Combination for Malaria Prophylaxis in Southeast Asia.
Cao, Y; Cui, L; Li, C; Li, X; Liu, H; Nie, R; Wang, H; Wang, J; Wang, Q; Yang, H, 2018
)
0.48
" The most common adverse events on dasotraline were insomnia, dry mouth, headache, decreased appetite, nausea, and anxiety."( Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial.
Deng, L; Goldman, R; Grilo, CM; Hudson, JI; Kent, J; Loebel, A; McElroy, SL; Navia, B; Tsai, J, 2021
)
0.62
" Both doses of dasotraline were generally safe and well-tolerated and resulted in global improvement on the BE-CGI-S, as well as improvement in BE related obsessional thoughts and compulsive behaviors on the YBOCS-BE."( Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial.
Deng, L; Goldman, R; Grilo, CM; Hudson, JI; Kent, J; Loebel, A; McElroy, SL; Navia, B; Tsai, J, 2021
)
0.62
" Follow-ups were conducted weekly to monitor for adverse events and malaria infections."( Efficacy and Safety of a Naphthoquine-Azithromycin Coformulation for Malaria Prophylaxis in Southeast Asia: A Phase 3, Double-blind, Randomized, Placebo-controlled Trial.
Cao, Y; Cui, L; Lakshmi, S; Li, C; Li, X; Liu, H; Menezes, L; Nie, R; Wang, H; Wang, J; Yang, H; Zhao, Y, 2021
)
0.62
" The most common adverse events in the dasotraline vs placebo groups were insomnia (44."( Efficacy and Safety of Dasotraline in Adults With Binge-Eating Disorder: A Randomized, Placebo-Controlled, Flexible-Dose Clinical Trial.
Deng, L; Goldman, R; Grilo, CM; Guerdjikova, AI; Hopkins, S; Hudson, JI; Koblan, KS; Loebel, A; McElroy, SL; Navia, B, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic properties of the newer specific serotonin (5-HT) reuptake inhibitors are reviewed."( Pharmacokinetics of the selective serotonin reuptake inhibitors.
DeVane, CL, 1992
)
0.28
" From a clinical point of view, it is of relevance that potency to inhibit the cytochrome P450 isozyme CYP2D6 gradually decreases from paroxetine, fluoxetine, norfluoxetine, desmethylcitalopram, fluvoxamine, and sertraline down to citalopram, explaining to a great extent differences in pharmacokinetic interactions between the SSRIs and tricyclic antidepressants, which are metabolized by this enzyme."( Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
Baumann, P; Rochat, B, 1995
)
0.29
"The pharmacokinetic interactions of sertraline and fluoxetine with the tricyclic antidepressant desipramine were studied in 18 healthy male volunteers phenotyped as extensive metabolizers of dextromethorphan."( Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.
Alderman, J; Chung, M; Harris, S; Harrison, W; Messig, M; Preskorn, SH, 1994
)
0.29
" Samples for pharmacokinetic analyses were obtained on Days 15 and 32; trough plasma concentrations of carbamazepine and its principal metabolite, carbamazepine-10, 11-epoxide (CBZ-E), were determined daily beginning on Day 13."( Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine.
Dewland, PM; Muirhead, DC; Rapeport, WG; Tanner, T; Wesnes, K; Williams, SA, 1996
)
0.29
"There were no significant differences between the sertraline and placebo groups in any of the pharmacokinetic parameters for carbamazepine or CBZ-E."( Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine.
Dewland, PM; Muirhead, DC; Rapeport, WG; Tanner, T; Wesnes, K; Williams, SA, 1996
)
0.29
"There were no significant differences between the sertraline group and the placebo group in the pharmacokinetic parameters of phenytoin."( Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin.
Cross, M; Muirhead, DC; Rapeport, WG; Wesnes, K; Williams, SA, 1996
)
0.29
"7-fold increase in Cmax and a significant prolongation in elimination half-life in hepatically impaired patients."( Influence of liver cirrhosis on sertraline pharmacokinetics.
Angebaud, P; Coates, P; Démolis, JL; Funck-Brentano, C; Grangé, JD; Jaillon, P, 1996
)
0.29
"A nonblinded study was conducted to compare the pharmacokinetic properties of the selective serotonin reuptake inhibitor sertraline in 22 young (aged 18 to 45 years) and 22 elderly (> 65 years) volunteers, of whom half were male and half were female."( Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers.
Ronfeld, RA; Tremaine, LM; Wilner, KD, 1997
)
0.3
" The pharmacokinetic analyses were based on data from 20 individuals."( Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers.
Baris, BA; Gardner, MJ; Preskorn, SH; Wilner, KD, 1997
)
0.3
" There were no significant treatment effects on the mean area under the plasma concentration-time curve (AUC), mean peak plasma sertraline concentration (Cmax), mean time to reach Cmax (tmax), mean terminal elimination half-life, or the mean elimination rate constant in either study."( Sertraline. Chronopharmacokinetics and the effect of coadministration with food.
Baris, BA; Ronfeld, RA; Wilner, KD, 1997
)
0.3
" An approximately 10-fold increase in the Cmax and AUC(24) of paroxetine and an approximately 2-fold increase in these parameters for sertraline occurred simultaneously with the desipramine concentration changes."( Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
Alderman, J; Allison, J; Chung, M; Greenblatt, DJ; Harrison, W; Penenberg, D; Preskorn, SH, 1997
)
0.3
"To examine the pharmacokinetic interaction between the selective serotonin reuptake inhibitor sertraline and the tricyclic antidepressants desipramine or imipramine in 12 healthy male subjects."( The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Kurtz, DL, 1997
)
0.3
"Multiple-dose, but not single-dose, treatment with sertraline significantly reduced apparent plasma clearance (CL/F) and prolonged the half-life of desipramine relative to baseline."( The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Kurtz, DL, 1997
)
0.3
"This pharmacokinetic interaction is likely the result of an inhibition of CYP2D6 tricyclic metabolism by sertraline."( The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Kurtz, DL, 1997
)
0.3
"Mean area under the plasma concentration-time curve (AUC), peak plasma concentration (Cmax), and elimination half-life (t1/2) for sertraline and desmethylsertraline were similar to previously reported adult values."( Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy.
Alderman, J; Chung, M; Johnston, HF; Wolkow, R, 1998
)
0.3
" For each sampling period for SER, area under the serum concentration versus time curve, maximal serum concentration (Cmax), and the time at which Cmax occurred (Tmax) were determined."( Pharmacokinetics of sertraline across pregnancy and postpartum.
Anthony, M; Davis, MF; Fankhauser, M; Freeman, MP; Fried, K; Moreno, F; Nolan, PE; Woosley, RL, 2008
)
0.35
" In an ADHD population treated with dasotraline 4 or 8 mg/day, dasotraline was characterized by a mean apparent half-life of 47 h and plasma concentrations reached steady-state by 10 days of dosing."( Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults.
Hing, J; Hopkins, SC; Koblan, KS; Loebel, A; Passarell, JA; Skende, E; Sunkaraneni, S, 2016
)
0.43
" A pharmacokinetic study was conducted in adults and children over 5 years of age (6 to 10, 11 to 17, and ≥18 years of age) with uncomplicated malaria in Tanzania."( Population Pharmacokinetics of Antimalarial Naphthoquine in Combination with Artemisinin in Tanzanian Children and Adults: Dose Optimization.
Abdulla, S; Ali, AM; Bakari, BM; Denti, P; Gausi, K; Gwandu, CH; Hamad, A; Jongo, SA; Juma, OA; Kassim, KR; Lweno, ON; Mbaga, TA; Milando, FA; Mkindi, C; Mtoro, AT; Penny, MA; Shekalaghe, SA; Simon, B, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" Ice packs combined with a cooling blanket and dantrolene 80 mg iv were administered to control fever and rigidity, respectively."( Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.
Graber, MA; Hoehns, TB; Perry, PJ, 1994
)
0.29
"Selective serotonin reuptake inhibitor antidepressants should not be combined with monoamine oxidase inhibitor antidepressants because of the risk of serotonin syndrome."( Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.
Graber, MA; Hoehns, TB; Perry, PJ, 1994
)
0.29
" To minimize the potential for an adverse event, the practitioner must remember the drug-drug interactions, and possible consequences when one of these antidepressants is being prescribed."( Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs.
Richelson, E, 1997
)
0.3
" The proposed method was based on two-dimensional online solid phase extraction combined with liquid chromatography tandem mass spectrometry (SPE/LC-MS/MS)."( Rapid determination of six carcinogenic primary aromatic amines in mainstream cigarette smoke by two-dimensional online solid phase extraction combined with liquid chromatography tandem mass spectrometry.
Bie, Z; Chen, Y; Ji, L; Lu, W; Ren, H; Zhu, Y, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" The reasons for the relative small absorption rate are discussed."( [On the absorption of decongestive nose-drops-investigation with a radioactive labelled imidazoline-derivate (author's transl)].
Eichner, H; Münzel, M, 1975
)
0.25
" They are well absorbed orally but exhibit an extensive first-pass extraction in the liver."( Pharmacokinetics of the selective serotonin reuptake inhibitors.
DeVane, CL, 1992
)
0.28
" Paroxetine is well absorbed from the gastrointestinal tract and undergoes first-pass metabolism that is partially saturable."( The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
Johnson, AM; Tulloch, IF, 1992
)
0.28
" The results of these 2 studies show that the bioavailability and elimination of sertraline tablets are not influenced by the time of administration or administration with or without food."( Sertraline. Chronopharmacokinetics and the effect of coadministration with food.
Baris, BA; Ronfeld, RA; Wilner, KD, 1997
)
0.3
"Predicting the reversible interactions between aromatic amines and soil is essential for assessing the mobility, bioavailability and exposure from contaminated sites."( Role of pH in partitioning and cation exchange of aromatic amines on water-saturated soils.
Fabrega, JR; Jafvert, CT; Lee, LS; Li, H, 2001
)
0.31

Dosage Studied

ExcerptRelevanceReference
"The pharmacology and pharmacokinetics, adverse effects, drug interactions, efficacy, and dosage and administration of the new selective serotonin reuptake inhibitors paroxetine, sertraline, and fluvoxamine are reviewed."( Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors.
Grimsley, SR; Jann, MW, 1992
)
0.28
" Furthermore, the SSRIs generally do not require dosage escalation for most patients and evidence indicates that they are effective in the treatment of depression associated with anxiety and insomnia."( Bridging the gap between psychiatric practice and primary care.
Thompson, C, 1992
)
0.28
" The first of these studies of a flexible dosing design showed that sertraline, given for eight weeks in daily dosages of 50-200 mg, was a safe and effective treatment for OCD, and superior to placebo."( Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies.
Chouinard, G, 1992
)
0.28
" There was no evidence for tolerance to the hypophagic and weight-loss effects of sertraline during either of the chronic dosing studies."( Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice.
Chapin, DS; Johnson, JL; Nielsen, JA; Torgersen, LK, 1992
)
0.28
" Once-daily dosing is recommended, with steady state being reached after about 7 days."( Clinical implications of the pharmacology of sertraline.
Warrington, SJ, 1991
)
0.28
" The incidence of side effects was related to both dosage and dosage regimen."( Toleration and safety of sertraline: experience worldwide.
Doogan, DP, 1991
)
0.28
" The primary adverse events associated with serotonin reuptake inhibitors involve the gastrointestinal system, although side effects may be less frequent at lower dosage levels."( Clinical overview of serotonin reuptake inhibitors.
Rickels, K; Schweizer, E, 1990
)
0.28
" After a 2-week titration period in which the once-daily sertraline dose was increased from 50 mg/day to a maximum of 200 mg/day, dosage was maintained until the end of the eighth week, then patients were titrated off medication over the next 2 weeks."( Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.
Bick, PA; Chouinard, G; Gaffney, M; Goodman, W; Greist, J; Hackett, E; Jenike, M; Rasmussen, S; White, K, 1990
)
0.28
" Chronic dosing produces down-regulation of beta-adrenergic receptors."( Sertraline: a new antidepressant.
Caillard, V; Doogan, DP, 1988
)
0.27
" Acute and repeated dosing of sertraline decreased serotonin content of whole blood."( Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin.
Browne, RG; Koe, BK; Weissman, A; Welch, WM, 1983
)
0.5
" The dose-response curve was similar to that obtained by 3H-thymidine assay."( Early changes in concanavalin A-stimulated lymphocytes detected by the fluorescent probe N-phenyl-1-naphthylamine.
Betts, RL; Halliday, GM; Hocking, GR; Nairn, RC; Rolland, JM, 1981
)
0.48
" Outpatients at a Veterans Affairs mental health clinic who were being treated with fluoxetine were randomly assigned to receive either 50 or 75 mg of sertraline hydrochloride for every 20 mg of fluoxetine (as the hydrochloride salt) or to continue to receive their current dosage of fluoxetine."( Clinical effect of converting antidepressant therapy from fluoxetine to sertraline.
Christenson, JL; Cushing, AG; Haider, A; Miller, DR; Station, RD, 1995
)
0.29
" The current study examined the efficacy, safety, and optimal dosing strategy of sertraline in patients with OCD."( Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder.
Chouinard, G; DuBoff, E; Greist, J; Halaris, A; Kim, SW; Koran, L; Liebowitz, M; Lydiard, RB; Rasmussen, S; White, K, 1995
)
0.29
" The starting dosage (sertraline 50 mg/day, fluoxetine 20 mg/day) was the final dosage in 76% of patients in both treatment groups."( A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression.
Bennie, EH; Martindale, JJ; Mullin, JM, 1995
)
0.29
" Its pharmacologic profile permits once-daily dosing while allowing plasma drug levels to equilibrate within 1 week."( The role of sertraline in the management of depression.
Shelton, RC,
)
0.13
" At t1/2 of 24 h makes once-daily dosing feasible and allows for new steady-state concentrations and wash-out within a reasonable time after dose adjustment."( Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline.
Preskorn, S, 1994
)
0.29
" Case study reports suggest that elderly persons are responsive to selective serotonin uptake inhibitors, although medication selection and dosage may need to be adjusted as a result of the medical conditions sometimes present in the elderly."( Treatment of obsessive compulsive disorder in the elderly: a review and case example.
Calamari, JE; Faber, SD; Hitsman, BL; Poppe, CJ, 1994
)
0.29
" The Regenstrief Medical Record System was used to analyze the dosing of SSRIs in the outpatient population of an urban teaching hospital."( Selective serotonin reuptake inhibitor dose titration in the naturalistic setting.
Coons, SJ; Gregor, KJ; McDonald, RC; Overhage, JM,
)
0.13
"Eleven patients meeting DSM-III-R criteria for at least one personality disorder were treated with sertraline in an open clinical trial with a flexible dosing schedule."( An open trial of sertraline in personality disordered patients with impulsive aggression.
Coccaro, EF; Kavoussi, RJ; Liu, J, 1994
)
0.29
" Concentrations in plasma were determined after 7 days of desipramine (50 mg/day) dosing alone, during the 21 days of desipramine and selective serotonin reuptake inhibitor (SSRI) coadministration (fluoxetine, 20 mg/day; sertraline, 50 mg/day), and for 21 days of continued desipramine administration after SSRI discontinuation."( Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.
Alderman, J; Chung, M; Harris, S; Harrison, W; Messig, M; Preskorn, SH, 1994
)
0.29
" In keeping with previous data obtained with other sigma receptor ligands, low doses of sertraline and of clorgyline potentiated selectively with a bell-shaped dose-response curve the effect of N-methyl-D-aspartate (NMDA) on pyramidal neurons in the CA3 region of the rat dorsal hippocampus."( Modification of the N-methyl-D-aspartate response by antidepressant sigma receptor ligands.
Bergeron, R; De Montigny, C; Debonnel, G, 1993
)
0.29
" Bruxism remitted in all patients after a decrease in antidepressant dosage (N = 1) or addition of buspirone (N = 3)."( SSRI-associated nocturnal bruxism in four patients.
Ellison, JM; Stanziani, P, 1993
)
0.29
" In addition, they suggest that a decrease in SSRI dosage or the addition of buspirone may relieve SSRI-associated nocturnal bruxism."( SSRI-associated nocturnal bruxism in four patients.
Ellison, JM; Stanziani, P, 1993
)
0.29
"With some limitations in interpreting the data, the findings of this study suggest that SSRI-associated female sexual dysfunction occurs at a higher rate than we previously thought, equal potentials in implicating female sexual side effects among three SSRIs, and the absence or the low incidence of female sexual adverse effects from bupropion, and that these side effects can be managed by waiting for a spontaneous remission, dosage reduction of SSRIs, substitution with bupropion and other antidepressants, or the use of an antidote."( Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients.
Hsu, JH; Shen, WW, 1995
)
0.29
" Side effects increased with increasing dosage but were usually mild and well tolerated."( Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo.
Abuzzahab, FS; Amin, M; Claghorn, JL; Dubé, S; Fabre, LF; Mendels, J; Petrie, WM; Small, JG, 1995
)
0.29
"The results of this study suggest that dosing adjustments of digoxin may not be necessary in patients receiving concomitant sertraline administration."( Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic findings.
Coates, PE; Dewland, PM; Forster, PL; Rapeport, WG, 1996
)
0.29
" Cognitive function testing was performed on Day 1 before carbamazepine dosing (baseline), Day 15 (carbamazepine alone), and Day 32 (carbamazepine plus sertraline or placebo)."( Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine.
Dewland, PM; Muirhead, DC; Rapeport, WG; Tanner, T; Wesnes, K; Williams, SA, 1996
)
0.29
" The plasma phenytoin concentration-time profile was determined on Day 7 before the start of sertraline or placebo dosing and at the end of dosing on Day 24."( Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin.
Cross, M; Muirhead, DC; Rapeport, WG; Wesnes, K; Williams, SA, 1996
)
0.29
" Cognitive function testing was performed before dosing and over a 24-hour period after dosing on Days 1, 2, and 25."( Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.
Oliver, SD; Rapeport, WG; Wesnes, K; Williams, SA, 1996
)
0.29
" Indeed, planned pharmacokinetic drug interactions at the level of P450s have been proposed to reduce cyclosporine dosage requirements, to reduce variability of TCA levels, and to manipulate the contribution of alternative metabolic pathways to minimize toxic effects."( Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II.
Harvey, AT; Preskorn, SH, 1996
)
0.29
"1 for protocols 1 and 2, respectively) in stimulating the 5-HTP-induced HTR and produced a bell-shaped dose-response curve."( The stimulatory and inhibitory components of cocaine's actions on the 5-HTP-induced 5-HT2A receptor response.
Darmani, NA; Reeves, SL, 1996
)
0.29
" The tramadol dosage had recently been increased, resulting in what was believed to be serotonergic syndrome."( Possible serotonin syndrome associated with tramadol and sertraline coadministration.
Blackburn, KH; Mason, BJ, 1997
)
0.3
"Serotonin syndrome is a toxic hyperserotonergic state that develops soon after initiation or dosage increments of the offending agent."( Possible serotonin syndrome associated with tramadol and sertraline coadministration.
Blackburn, KH; Mason, BJ, 1997
)
0.3
" In this study, sertraline was administered at a dosage of 200mg once daily (the maximum recommended daily dosage) for 21 days after upward dosage titration from 50 mg/day over a 9-day period."( Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers.
Ronfeld, RA; Tremaine, LM; Wilner, KD, 1997
)
0.3
" There was a small but statistically significant decrease (16%) in the clearance of tolbutamide in patients receiving the maximum recommended dosage of sertraline."( A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.
Preskorn, SH; Tremaine, LM; Wilner, KD, 1997
)
0.3
" These results suggest that sertraline at the maximum recommended dosage under steady-state conditions, and demethylsertraline, the principal metabolite of sertraline, are unlikely to exert significant inhibitory effects on the CYP2C19 and CYP3A3/4 hepatic isoenzymes responsible for the metabolism of diazepam."( Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers.
Baris, BA; Gardner, MJ; Preskorn, SH; Wilner, KD, 1997
)
0.3
" The dose-response curve was biphasic for citalopram with a maximum of 64% inhibition."( Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
Meier, E; Sánchez, C, 1997
)
0.3
"With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy."( Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
Baldessarini, RJ; Bodkin, JA; Gardner, DM; Lasser, RA; Wines, JD, 1997
)
0.3
"A sustained-release formulation of bupropion (bupropion SR), developed with an improved pharmacokinetic profile to permit less frequent dosing than the immediate-release form, has not been evaluated in active comparator trials."( Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.
Ascher, JA; Hughes, AR; Johnston, JA; Kavoussi, RJ; Segraves, RT, 1997
)
0.3
" The dosage of sertraline ranged from 25 to 150 mg/day (93."( The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline.
Herrmann, N; Kalow, W; Naranjo, CA; Ozdemir, V; Reed, K; Sellers, EM; Shulman, RW, 1998
)
0.3
" In case 2, a 25 mg reduction in the total daily dose of sertraline resulted in halving of the lamotrigine blood level even though the lamotrigine dosage was increased by 33%."( Lamotrigine toxicity secondary to sertraline.
Gerner, R; Kaufman, KR, 1998
)
0.3
" An antidepressant drug utilization review study performed in two different HMO models revealed important variations among available SSRI therapies in terms of dosage escalation and discontinuation, as well as concomitant medication costs associated with treating side effects."( Antidepressant utilization in managed care: an evaluation of SSRI use in two HMO settings.
Navarro, R; Spangler, M; Valler, WE, 1995
)
0.29
" When rats were dosed with indinavir as a P450 3A probe substrate, plasma exposure to indinavir increased three-fold following pretreatment with 1, consistent with drug-drug interaction projections based on the k(inact) and K(I) parameters for 1 in rat liver microsomes."( Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists.
Baillie, TA; Bakshi, RK; Chen, Q; Dean, DC; Miller, RR; Nargund, RP; Ngui, J; Stearns, RA; Tang, W; Wang, RW, 2008
)
0.35
"Insufficient data inform dosing of antidepressants and clinical monitoring for major depressive disorder (MDD) during the perinatal period."( Pharmacokinetics of sertraline across pregnancy and postpartum.
Anthony, M; Davis, MF; Fankhauser, M; Freeman, MP; Fried, K; Moreno, F; Nolan, PE; Woosley, RL, 2008
)
0.35
" This study provides preliminary evidence that once-daily dosing with dasotraline, a long-acting, dual monoamine reuptake inhibitor, may be a safe and efficacious treatment for adult ADHD."( Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults.
Goldman, R; Hopkins, SC; Jin, F; Koblan, KS; Kollins, SH; Loebel, A; Sarma, K, 2015
)
0.42
"These results related dasotraline pharmacokinetics to pharmacological activity in ADHD, and support the novel concept that maintaining constant, steady-state dopamine and norepinephrine reuptake inhibition throughout a 24-h dosing interval is a novel pharmacological approach to the management of ADHD symptoms."( Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults.
Hing, J; Hopkins, SC; Koblan, KS; Loebel, A; Passarell, JA; Skende, E; Sunkaraneni, S, 2016
)
0.43
" Male and female dogs were dosed daily by oral gavage with NP at 2, 10, or 50 mg/kg/day for a maximum of 14 days."( Naphthoquine-induced Central Nervous System and Hepatic Vasculocentric Toxicity in the Beagle Dog.
Galarneau, JR; Hall, RL; Li, W; Meseck, EK; Weaver, ML, 2016
)
0.43
" A regression analysis confirmed a significant linear dose-response relationship for dasotraline."( Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial.
Adler, LA; Findling, RL; Goldman, R; Hopkins, SC; Hsu, J; Kent, J; Koblan, KS; Loebel, A; Spencer, TJ, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
naphthylamineA primary arylamine that is naphthalene substituted by an amino group at unspecified position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (45)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency3.98110.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID893
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.24340.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency9.31770.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency61.76530.000221.22318,912.5098AID1259243; AID743036
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency19.95260.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency15.44900.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency43.56450.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency48.55770.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency24.54120.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency21.82240.003041.611522,387.1992AID1159552
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency10.10340.001530.607315,848.9004AID1224841; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency54.99240.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency25.74620.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743078
aryl hydrocarbon receptorHomo sapiens (human)Potency25.87950.000723.06741,258.9301AID651777; AID743085; AID743122
thyroid stimulating hormone receptorHomo sapiens (human)Potency76.95880.001628.015177.1139AID1259385
activating transcription factor 6Homo sapiens (human)Potency26.73490.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency48.966219.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency44.97880.057821.109761.2679AID1159526; AID1159528
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency10.00000.001815.663839.8107AID894
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.61500.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency33.18770.000627.21521,122.0200AID651741; AID720636; AID743219
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency44.30170.001557.789015,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency44.30170.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Kelch-like ECH-associated protein 1Homo sapiens (human)Kd1,200.00001.00001.76672.4000AID1776033
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
in utero embryonic developmentKelch-like ECH-associated protein 1Homo sapiens (human)
ubiquitin-dependent protein catabolic processKelch-like ECH-associated protein 1Homo sapiens (human)
regulation of autophagyKelch-like ECH-associated protein 1Homo sapiens (human)
protein ubiquitinationKelch-like ECH-associated protein 1Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processKelch-like ECH-associated protein 1Homo sapiens (human)
cellular response to oxidative stressKelch-like ECH-associated protein 1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityKelch-like ECH-associated protein 1Homo sapiens (human)
regulation of epidermal cell differentiationKelch-like ECH-associated protein 1Homo sapiens (human)
cellular response to interleukin-4Kelch-like ECH-associated protein 1Homo sapiens (human)
negative regulation of response to oxidative stressKelch-like ECH-associated protein 1Homo sapiens (human)
regulation of autophagyHistone acetyltransferase KAT8Homo sapiens (human)
negative regulation of epithelial to mesenchymal transitionHistone acetyltransferase KAT8Homo sapiens (human)
neurogenesisHistone acetyltransferase KAT8Homo sapiens (human)
myeloid cell differentiationHistone acetyltransferase KAT8Homo sapiens (human)
negative regulation of type I interferon productionHistone acetyltransferase KAT8Homo sapiens (human)
post-embryonic hemopoiesisHistone acetyltransferase KAT8Homo sapiens (human)
transcription initiation-coupled chromatin remodelingHistone acetyltransferase KAT8Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone acetyltransferase KAT8Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone acetyltransferase KAT8Homo sapiens (human)
oogenesisHistone acetyltransferase KAT8Homo sapiens (human)
regulation of mRNA processingHistone acetyltransferase KAT8Homo sapiens (human)
positive regulation of transcription initiation by RNA polymerase IIHistone acetyltransferase KAT8Homo sapiens (human)
positive regulation of skeletal muscle satellite cell differentiationHistone acetyltransferase KAT8Homo sapiens (human)
regulation of mitochondrial transcriptionHistone acetyltransferase KAT8Homo sapiens (human)
regulation of transcription by RNA polymerase IIHistone acetyltransferase KAT8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
protein bindingKelch-like ECH-associated protein 1Homo sapiens (human)
identical protein bindingKelch-like ECH-associated protein 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingKelch-like ECH-associated protein 1Homo sapiens (human)
disordered domain specific bindingKelch-like ECH-associated protein 1Homo sapiens (human)
ubiquitin-like ligase-substrate adaptor activityKelch-like ECH-associated protein 1Homo sapiens (human)
transcription factor bindingKelch-like ECH-associated protein 1Homo sapiens (human)
histone H4K5 acetyltransferase activityHistone acetyltransferase KAT8Homo sapiens (human)
histone H4K8 acetyltransferase activityHistone acetyltransferase KAT8Homo sapiens (human)
histone H4K16 acetyltransferase activityHistone acetyltransferase KAT8Homo sapiens (human)
transcription coactivator activityHistone acetyltransferase KAT8Homo sapiens (human)
protein bindingHistone acetyltransferase KAT8Homo sapiens (human)
histone H4 acetyltransferase activityHistone acetyltransferase KAT8Homo sapiens (human)
enzyme bindingHistone acetyltransferase KAT8Homo sapiens (human)
histone H4K5 acetyltransferase activityHistone acetyltransferase KAT8Homo sapiens (human)
histone H4K8 acetyltransferase activityHistone acetyltransferase KAT8Homo sapiens (human)
metal ion bindingHistone acetyltransferase KAT8Homo sapiens (human)
histone H4K16 acetyltransferase activityHistone acetyltransferase KAT8Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone acetyltransferase KAT8Homo sapiens (human)
peptide-lysine-N-acetyltransferase activityHistone acetyltransferase KAT8Homo sapiens (human)
protein propionyltransferase activityHistone acetyltransferase KAT8Homo sapiens (human)
transcription coregulator activityHistone acetyltransferase KAT8Homo sapiens (human)
chromatin bindingHistone acetyltransferase KAT8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleoplasmKelch-like ECH-associated protein 1Homo sapiens (human)
cytoplasmKelch-like ECH-associated protein 1Homo sapiens (human)
endoplasmic reticulumKelch-like ECH-associated protein 1Homo sapiens (human)
cytosolKelch-like ECH-associated protein 1Homo sapiens (human)
actin filamentKelch-like ECH-associated protein 1Homo sapiens (human)
inclusion bodyKelch-like ECH-associated protein 1Homo sapiens (human)
midbodyKelch-like ECH-associated protein 1Homo sapiens (human)
centriolar satelliteKelch-like ECH-associated protein 1Homo sapiens (human)
Cul3-RING ubiquitin ligase complexKelch-like ECH-associated protein 1Homo sapiens (human)
nucleusHistone acetyltransferase KAT8Homo sapiens (human)
chromosomeHistone acetyltransferase KAT8Homo sapiens (human)
kinetochoreHistone acetyltransferase KAT8Homo sapiens (human)
nucleusHistone acetyltransferase KAT8Homo sapiens (human)
nucleoplasmHistone acetyltransferase KAT8Homo sapiens (human)
mitochondrionHistone acetyltransferase KAT8Homo sapiens (human)
nuclear matrixHistone acetyltransferase KAT8Homo sapiens (human)
NSL complexHistone acetyltransferase KAT8Homo sapiens (human)
MSL complexHistone acetyltransferase KAT8Homo sapiens (human)
histone acetyltransferase complexHistone acetyltransferase KAT8Homo sapiens (human)
MLL1 complexHistone acetyltransferase KAT8Homo sapiens (human)
chromatinHistone acetyltransferase KAT8Homo sapiens (human)
NuA4 histone acetyltransferase complexHistone acetyltransferase KAT8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624614Specific activity of expressed human recombinant UGT2A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID681336TP_TRANSPORTER: cell accumulation of 0.05u daunomycin in MCF-7/ADR cells2004Journal of pharmaceutical sciences, Jul, Volume: 93, Issue:7
Effects of benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport.
AID624610Specific activity of expressed human recombinant UGT1A72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID203473Binding constant against bovine serum albumin1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID1776033Binding affinity to human recombinant His-tagged Keap1 Kelch domain (321 to 609 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissociation constant by surface plasmon resonance method2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1278462Induction of ROS generation in human NCI-H1299 cells at <= 100 uM after 5 hrs by DCF-DA staining-based assay2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Carbohydrate-based inducers of cellular stress for targeting cancer cells.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID23978Capacity ratio (log k'w)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1776034Binding affinity to human recombinant His-tagged Keap1 Kelch domain (321 to 609 residues) expressed in Escherichia coli BL21 (DE3) at 1 mM by saturation transfer difference-NMR analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
AID1507709Inhibition of N-terminal His6-tagged KAT8 catalytic domain (125 to 458 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) using SGRGKGGKGLGKGGAKRHRK-NH2 as substrate after 5 mins in presence of Ac-CoA by fluorescence assay2017European journal of medicinal chemistry, Aug-18, Volume: 136The relevance of K
AID1507730Inhibition of N-terminal His6-tagged KAT8 catalytic domain (125 to 458 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) at 200 uM using SGRGKGGKGLGKGGAKRHRK-NH2 as substrate after 5 mins in presence of Ac-CoA by fluorescence assay2017European journal of medicinal chemistry, Aug-18, Volume: 136The relevance of K
AID23714Partition coefficient (logP)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID160321Competition for [3H]benzo[a]pyrene-binding site of polycyclic aromatic hydrocarbon binding protein (PBP) from mouse liver1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Voronoi binding site model of a polycyclic aromatic hydrocarbon binding protein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,024)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990165 (16.11)18.7374
1990's543 (53.03)18.2507
2000's106 (10.35)29.6817
2010's170 (16.60)24.3611
2020's40 (3.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.03 (24.57)
Research Supply Index7.11 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index88.44 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials137 (12.59%)5.53%
Reviews82 (7.54%)6.00%
Case Studies188 (17.28%)4.05%
Observational0 (0.00%)0.25%
Other681 (62.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]